Multi-functional analgesic-releasing wound dressing
A wound dressing including a porous biosynthetic polymer film comprising a poly(lactide-co-caprolactone) (“PLC”) copolymer or other suitable polymer matrix, and a local analgesic loaded therein, to provide pain relief over an extended period of time (e.g., for 5-7 days), e.g., for healing of a partial thickness dermal injury. The PLC copolymer may have a particular lactide/caprolactone molar ratio (e.g., from 2:1 to 9:1) to ensure slow, sustained release of the bupivacaine or other analgesic. The dressing may provide a water vapor transmission rate from 1000 g/m 2 ·day to 3000 g/m 2 ·day to facilitate fast healing and regrowth of new epithelial tissue beneath the dressing. The dressing is configured to remain positioned over the dermal injury, providing wound protection for about 14 days, after which is simply debrides away, falls off, or is easily and painlessly removed, once new epithelial tissue regrows.
1. An analgesic-releasing wound dressing comprising:
a porous biosynthetic polymer film; and
a local analgesic impregnated within the porous biosynthetic polymer film;
wherein the wound dressing provides sustained release of the local analgesic over a period of at least 1 day, with a burst phase where at least 60% of total analgesic is released within 1-3 days;
wherein the local analgesic is loaded into the porous biosynthetic polymer film in an amount from 5% to 20% relative to the porous biosynthetic polymer film,
wherein the analgesic-releasing wound dressing is a single, substantially homogenous layer, without any additional complex construction, and
wherein 70-90% of a volume of the wound dressing comprises pores.
2. The wound dressing of claim 1 , wherein the porous biosynthetic polymer film comprises at least one of a poly (lactide-co-caprolactone) copolymer, PLA, PLGA or PCL.
3. The wound dressing of claim 1 , wherein the local analgesic comprises a small molecule analgesic having a molecular weight of less than 500 Daltons that is hydrophobic.
4. The wound dressing of claim 3 , wherein the hydrophobic local analgesic has a partition coefficient (log P) value of at least 2.0.
5. The wound dressing of claim 1 , wherein the local analgesic comprises an amide local analgesic selected from one or more of bupivacaine, levobupivacaine, lidocaine, prilocaine, or ropivacaine.
6. The wound dressing of claim 1 , wherein the wound dressing provides sustained release of the local analgesic over a period of at least 2 days, or over a period of from 1 to 3 days, 3 to 5 days, 3 to 7 days, or 4 to 7 days.
7. The wound dressing of claim 1 , wherein the porous biosynthetic polymer film has a lactide/caprolactone molar ratio from 2:1 to 10:1.
8. The wound dressing of claim 1 , wherein the porous biosynthetic polymer film has a water vapor transmission rate from 1000 g/m 2 ·day to 3000 g/m 2 ·day.
9. The wound dressing of claim 1 , wherein the local analgesic is loaded into the porous biosynthetic polymer film in an amount from 10% to 15% by weight.
10. The wound dressing of claim 1 , wherein the wound dressing is consists of a single layer, being substantially homogenous throughout a thickness thereof.
11. The wound dressing of claim 1 , wherein the wound dressing has a thickness of at least 200 μm, up to 2 mm, or up to 1 mm.
12. The wound dressing of claim 1 , wherein the porous biosynthetic polymer film further comprises hyaluronic acid, and/or the wound dressing further comprises an antimicrobial agent incorporated into the wound dressing.
13. The analgesic-releasing wound dressing as recited in claim 1 , wherein the wound dressing consists of a single layer, and wherein:
the porous biosynthetic polymer film comprises a poly (lactide-co-caprolactone) copolymer, having a lactide/caprolactone molar ratio from 2:1 to 9:1, and having a water vapor transmission rate from 1000 g/m 2 ·day to 3000 g/m 2 ·day, wherein the biosynthetic polymer film is resorbable or dissolvable when positioned for use over a partial thickness dermal injury of a patient, so as to remain in place, providing wound protection for at least 10 days, but debriding or falling off naturally within 20 days when positioned over a partial thickness dermal injury of a patient; and
the local analgesic impregnated within the porous biosynthetic polymer film comprises an amide analgesic having a partition coefficient (log P) value from 3.0 to 3.8, the analgesic being impregnated within the porous biosynthetic polymer film at a weight fraction of from 5-20% relative to the porous biosynthetic polymer film, wherein the wound dressing provides sustained release of the analgesic over a period of at least 1 day and at least 60% of the total analgesic is released within 1-3 days.
14. The wound dressing of claim 1 , wherein the porous biosynthetic polymer film has a pore size of no more than 50 microns.
15. The wound dressing of claim 1 , wherein the wound dressing has an elastic modulus of from 400-1000 N/mm 2 and an elongation at break of from 100%-200%.
16. A method of treating pain associated with a partial thickness dermal injury, the method comprising:
providing a wound dressing, wherein the wound dressing consists of a single, substantially homogenous layer the wound dressing including:
a porous biosynthetic polymer film comprising a poly (lactide-co-caprolactone) copolymer; and
a local analgesic impregnated within the porous biosynthetic polymer film, wherein the wound dressing provides sustained release of the local analgesic while reducing pain over a sustained period of time of at least 1 day;
wherein the wound dressing remains in place over the partial thickness dermal injury for a full duration of healing thereof, without removal of the wound dressing for any wound dressing changes, said full duration of healing being about 14 days, wherein the wound dressing releases a burst of at least 60% of the local analgesic over days 1-3 after application over the partial thickness dermal injury, followed by a sustained tapered release from days 4-7 after application, wherein 70-90% of a volume of the wound dressing comprises pores, wherein the wound dressing falls off naturally within 20 days, and wherein polymer weight loss and loss of mechanical properties of the wound dressing is less than 10% within the full duration of healing.
17. The method of claim 16 , wherein the local analgesic comprises an amide local analgesic comprising at least one of bupivacaine, levobupivacaine, lidocaine, prilocaine, or ropivacaine.
18. The method of claim 16 , wherein the biosynthetic polymer film is resorbable or dissolvable when positioned for use over the partial thickness dermal injury of a patient, so as to remain in place, providing wound protection for about 14 days, but debriding or falling off naturally within 20 days when positioned over the partial thickness dermal injury of a patient.
19. An analgesic-releasing wound dressing comprising:
a porous biosynthetic polymer film; and
a local analgesic impregnated within the porous biosynthetic polymer film;
wherein:
the wound dressing provides sustained release of the local analgesic over a period of at least 1 day, with a burst phase where at least 60% of total analgesic is released within 1-3 days,
the local analgesic is loaded into the porous biosynthetic polymer film in an amount from 5% to 20% relative to the porous biosynthetic polymer film,
the analgesic-releasing wound dressing consists of a single, substantially homogenous layer,
the wound dressing has a thickness of at least 200 μm, and up to 2 mm,
70-90% of a volume of the wound dressing comprises pores,
the wound dressing provides protection for at least 10 days, but debriding or falling off naturally within 20 days when positioned over a partial thickness dermal injury of a patient, and
polymer weight loss and loss of mechanical properties of the wound dressing is less than 10% within a full duration of healing.